New advances in targeted therapy and immunotherapy of acute myelogenous leukemia / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 9-16, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-862787
ABSTRACT
Acute myelogenous leukemia (AML) is a highly heterogeneous malignant hematologic disease, and it is mainly treated with traditional chemotherapy, but the efficacy is limited and the patients with worse performance status and comorbidities can not be treated with chemotherapy. Gene changes play an important role in the diagnosis and prognosis of AML, and these gene changes also provide targets for molecular targeted therapy. Meanwhlie, immunotherapy has achieved certain curative effects in AML and has a promising prospect. In this review, targeted therapy and immunotherapy of AML reported in 61st American Society of Hematology (ASH) Annual Meeting are summarized.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Leukemia & Lymphoma
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS